Table S3. Comparison of concentrations of TMs in MPE, TPE and other BPE*.
| Variable | Beijing cohort (derivation) | Wuhan cohort (validation) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| MPE (n=67) | TPE (n=61) | Other BPE (n=46) | P# | MPE (n=52) | TPE (n=78) | Non-TPE (n=23) | P# | ||
| CEA | |||||||||
| PE, ng/mL | 69.5 | 0.6 | 0.6 | − | 82.3 | 0.9 | 0.7 | − | |
| (7.7‒919.1) | (0.5‒1.0) | (0.5‒2.1) | (11.0‒832.8) | (0.5‒1.3) | (0.5‒1.6) | ||||
| Serum, ng/mL | 4.4 | 1.2 | 2.1 | − | 7.7 | 1.6 | 2.1 | − | |
| (2.1‒29.5) | (0.8‒2.2) | (1.3‒3.1) | (2.0‒43.9) | (0.9‒2.3) | (1.5‒3.1) | ||||
| PE/serum ratio | 10.2 | 0.6 | 0.5 | − | 7.2 | 0.6 | 0.4 | − | |
| (1.1‒29.7) | (0.5‒0.8) | (0.3‒0.8) | (1.5‒28.3) | (0.5‒0.7) | (0.2‒0.7) | ||||
| ∆PE–serum, ng/mL | 46.6 | −0.5 | −0.8 | − | 53.7 | −0.6 | −1.2 | − | |
| (0.3‒701.6) | (−0.9‒0.22) | (−1.4 to −0.3) | (4.2‒804.2) | (−1.2 to −0.3) | (−2.6 to −0.3) | ||||
| CA125 | |||||||||
| PE, U/mL | 946.7 | 407.9 | 298.7 | − | 657.8 | 637.1 | 543.6 | − | |
| (374.0‒2835.7) | (195.4‒831.2) | (90.8‒753.9) | (395.1‒1366.3) | (203.1‒983.7) | (320.3‒1209.5) | ||||
| Serum, U/mL | 90.7 | 112.2 | 86.8 | − | 85.2 | 132.1 | 124.1 | − | |
| (40.6‒229.2) | (66.1‒180.3) | (37.2‒168.3) | (44.1‒222.5) | (78.1‒214.8) | (92.0‒271.2) | ||||
| PE/serum ratio | 8.5 | 3.4 | 3.5 | − | 6.2 | 3.7 | 4.5 | − | |
| (4.4‒19.0) | (1.5‒7.3) | (1.2‒5.9) | (3.3‒12.7) | (1.9‒6.5) | (2.1‒7.4) | ||||
| ∆PE–serum, U/mL | 895.0 | 279.1 | 194.9 | − | 425.4 | 412.2 | 380.0 | − | |
| (280.2‒2046.8) | (72.1‒713.1) | (47.0‒482.0) | (205.3‒1058.6) | (119.4‒806.4) | (197.6‒1085.4) | ||||
| CA15-3 | |||||||||
| PE, U/mL | 30.1 | 6.6 | 3.5 | <0.001 | 47.6 | 7.7 | 2.2 | <0.001 | |
| (5.4‒91.7) | (4.6‒10.8) | (2.0‒7.6) | (11.8‒176.0) | (5.6‒10.1) | (1.4‒4.7) | ||||
| Serum, U/mL | 15.7 | 8.9 | 9.9 | − | 21.3 | 10.7 | 11.0 | − | |
| (8.8‒33.6) | (6.7‒12.5) | (6.8‒16.9) | (13.3‒70.8) | (6.8‒15.0) | (7.6‒18.0) | ||||
| PE/serum ratio | 1.3 | 0.7 | 0.4 | <0.001 | 1.1 | 0.8 | 0.3 | <0.001 | |
| (0.6‒3.5) | (0.6‒1.0) | (0.3‒0.6) | (0.5‒3.5) | (0.5‒0.9) | (0.1‒0.4) | ||||
| ∆PE–serum, U/mL | 8.4 | −1.9 | −6.1 | <0.001 | 4.2 | −2.1 | −6.4 | <0.001 | |
| (−4.1‒53.7) | (−4.9 to −0.1) | (−10.5 to −3.3) | (−6.6‒85.2) | (−5.3 to −0.7) | (−14.3 to −4.5) | ||||
| CA19-9 | |||||||||
| PE,U/mL | 24.8 | 2.0 | 2.0 | − | 13.0 | 2.8 | 2.0 | − | |
| (2.0‒1089.2) | (2.0‒3.0) | (2.0‒3.7) | (2.0‒291.2) | (2.0‒6.2) | (2.0‒3.5) | ||||
| Serum, U/mL | 14.4 | 4.3 | 6.9 | − | 8.8 | 7.2 | 7.7 | − | |
| (5.3‒61.3) | (2.2‒8.7) | (2.9‒16.1) | (2.5‒58.8) | (4.2‒12.6) | (2.7‒15.1) | ||||
| PE/serum ratio | 1.0 | 0.6 | 0.5 | − | 1.0 | 0.4 | 0.5 | − | |
| (0.6‒9.3) | (0.4‒1.0) | (0.3‒0.9) | (0.8‒8.8) | (0.3‒0.7) | (0.1‒0.9) | ||||
| ∆PE–serum, U/mL | 0 | −1.74 | −2.8 | − | 0.6 | −4.1 | −4.2 | − | |
| (−3.8‒425.4) | (−5.62‒0.0) | (−7.0 to −0.4) | (−0.9‒237.3) | (−7.6 to −1.4) | (−12.0 to −0.3) | ||||
*, data are presented as medians (25th to 75th percentiles); #, comparison between concentrations in TPE and other BPE. MPE, malignant pleural effusion; BPE, benign pleural effusion; PE, pleural effusion; TPE, tuberculosis pleural effusion; TMs, tumor markers; CEA, carcinoembryonic antigen.